Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Hoth Therapeutics Inc | HOTH | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.18 | 04:15:25 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.18 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.99 - 4.30 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.18 | USD |
Hoth Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.13M | 4.35M | - | 0 | -7.85M | -1.80 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Hoth Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HOTH Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.31 | 1.31 | 1.15 | 1.20 | 40,376 | -0.13 | -9.92% |
| 1 Month | 1.64 | 1.6401 | 1.15 | 1.39 | 264,811 | -0.46 | -28.05% |
| 3 Months | 1.30 | 1.67 | 1.15 | 1.37 | 476,220 | -0.12 | -9.23% |
| 6 Months | 1.37 | 1.73 | 0.99 | 1.39 | 358,341 | -0.19 | -13.87% |
| 1 Year | 2.15 | 4.30 | 0.99 | 2.64 | 695,578 | -0.97 | -45.12% |
| 3 Years | 39.00 | 55.00 | 0.99 | 22.03 | 1,414,499 | -37.82 | -96.97% |
| 5 Years | 112.75 | 226.75 | 0.99 | 34.89 | 1,228,536 | -111.57 | -98.95% |
Hoth Therapeutics Description
| Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups. |
